stockportfolio.pro
Adaptive Biotechnologies Corporation (ADPT)
Healthcare · Diagnostics & Research · NasdaqGS
Adaptive Biotechnologies Corporation revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.45M | $55.66M | $85.07M | $98.38M | $154.34M | $185.31M | $170.28M | $178.96M | $276.98M |
| Gross profit | $22.77M | $35.99M | $62.80M | $75.85M | $105.04M | $127.40M | $94.72M | $106.88M | $205.62M |
| Net income | $-42.83M | $-46.45M | $-68.61M | $-146.23M | $-207.28M | $-200.19M | $-225.25M | $-159.49M | $-59.50M |
| Net margin | -111.4% | -83.4% | -80.6% | -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
Source: Adaptive Biotechnologies Corporation SEC filings (10-K).
Explore 9 years of Adaptive Biotechnologies Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ADPT in your portfolio →
Adaptive Biotechnologies Corporation financial history by metric
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies Corporation — frequently asked questions
What is Adaptive Biotechnologies Corporation's revenue?
Adaptive Biotechnologies Corporation (ADPT) reported revenue of $276.98M for fiscal year 2025, up 54.8% from the prior year, according to its SEC filings.
Is Adaptive Biotechnologies Corporation profitable?
No — ADPT reported a net loss of $-59.50M in fiscal 2025.
What is ADPT's P/E ratio?
Adaptive Biotechnologies Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Adaptive Biotechnologies Corporation growing?
ADPT's revenue grew at roughly 23.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Adaptive Biotechnologies Corporation have?
As of fiscal year 2025, ADPT carried roughly $126.57M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Adaptive Biotechnologies Corporation's gross margin?
ADPT's gross margin was 74.2% in fiscal 2025 — gross profit of $205.62M on revenue of $276.98M.
What is Adaptive Biotechnologies Corporation's market cap?
Adaptive Biotechnologies Corporation (ADPT) has a market capitalization of about $3.00B, based on the latest data in our nightly-refreshed cache.
When does Adaptive Biotechnologies Corporation's fiscal year end?
ADPT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Adaptive Biotechnologies Corporation's official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.